SG
BIIB icon

Societe Generale’s Biogen BIIB Stock Holding History

Societe Generale’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$1.8M Buy
+129,300
New +$34.1M 0.01% 903

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Societe Generale's BIIB Position: Q2 2016 in Review

Societe Generale opened a new position in Biogen (BIIB) in Q2 2016: 32,226 shares worth $7.79M. The stake represents 0.06% of the portfolio and ranks #266 among its holdings.

965 funds tracked by Wall St. Rank hold BIIB as of Q2 2016.

  • Societe Generale held 32,226 shares of Biogen worth $7.79M as of Q2 2016.
  • Biogen was a new Societe Generale position in Q2 2016.
  • Biogen made up 0.06% of Societe Generale's portfolio in Q2 2016, its #266 holding.
  • 965 funds tracked by Wall St. Rank held Biogen as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.